The president, the portfolio, and the disappearing investigation

The Justice Department has dropped a criminal probe into an Abbott baby-formula plant — and the president of the United States is on record, twice in two days, saying he is profiting from a stock market he claims credit for. The proximity is uncomfortable enough on its own. The reporting that surfaced around it makes it harder still.

On 30 June 2026, President Donald Trump signed a declaration of a power emergency for the nation's largest electrical grid ahead of an extreme heat wave, a separate decision with its own political weight. The more pointed story is older, and it concerns a company, a portfolio, and a closed file. According to a thread circulated on 1 July by the market-news account Unusual Whales, the Department of Justice ended a criminal investigation into an Abbott Laboratories baby-formula facility the day before — 30 June — citing the same account. Reporting by MorePerfectUnion, referenced in the same thread, says Trump purchased up to $500,000 of Abbott stock roughly two months before that closure.

Taken together, the two data points describe a conflict of interest the size of a regulatory agency. They also describe something more durable: a presidency that has chosen, repeatedly and on the record, to talk about markets as something the office participates in rather than regulates.

The president's own description

The conflict is not a matter of inference. On 1 July 2026, the same day the Abbott news circulated, Trump told reporters — again per Unusual Whales' thread of public remarks — that "I am profiting because of the stock market going up," and added separately that he is "benefiting from the stock market gains." A third item in the thread has him stating that "independent funds manage his investments while he is President."

That last formulation is the one his lawyers have used for months. It is also the one most directly under strain. An independent manager can structure trades; it cannot insulate the officeholder from the appearance of self-dealing when the timing of a Justice Department action lines up with his disclosed position in the same company.

The Abbott probe concerned a facility at the centre of the 2022 infant-formula shortage, in which contamination led to a nationwide recall and a weeks-long collapse in supply. A criminal investigation of the sort now closed would have examined whether Abbott's practices at the plant crossed the line from civil violation into criminal negligence. Whatever the merits of the underlying case, the optics of the closure now belong to the White House.

The pattern, not the anomaly

The Abbott timing fits a pattern this publication has tracked since the start of the term. Public statements tying presidential success to the direction of equity markets are not new; the novelty here is the explicit acknowledgement of personal profit. A president describing himself as a beneficiary of the index he is also credited with moving is a different proposition from one who merely points to the charts at a rally.

Markets themselves, of course, are not the only thing a president moves. The same day the Abbott news broke, Trump declared a power emergency for the largest US grid ahead of a forecast heat wave — a step that gives the administration discretion over dispatch and pricing across a multi-state system serving tens of millions of households. The decision was reported by the prediction-market account Polymarket. It is a separate story; it is also part of the same governance question. When the executive treats both his portfolio and the grid as discretionary instruments, the line between public duty and private position thins in ways the existing ethics architecture was not built to police.

What the framework permits

US conflict-of-interest law for the presidency is famously thin. The president is not subject to the statutory disclosure regime that binds cabinet officers and senior political appointees. The Office of Government Ethics has no jurisdiction over the White House itself. Recusal norms exist; they are voluntary; they are not enforced. Independent management of a portfolio, in the form Trump describes, is the standard structural mitigation — and it is, by design, a mitigation that leaves the holder in possession of the upside while outsourcing the day-to-day decisions.

What it cannot do is break the link between policy actions and asset prices. A DOJ closure, an FDA inspection regime, a tariff waiver, a power-emergency declaration — each is a price-moving event for at least one publicly listed company. The mechanism the law provides is disclosure after the fact. The mechanism it does not provide is a check in advance.

What remains uncertain

The Unusual Whales thread is a rapid aggregation of public reporting and public statements; it is not itself a primary document. The original MorePerfectUnion reporting on the Abbott purchase — including the size of the position and the precise timing relative to the DOJ action — needs to be read against any subsequent disclosure filings, which lag the transactions by weeks. The DOJ's stated rationale for closing the probe has not, in the items available to this publication, been spelled out. Independent confirmation of the sequence, and of the rationale, is the next thing worth waiting for.

What does not need waiting for is the framing. A president who says he is profiting from a market he also claims credit for has made the structural argument against himself. The Abbott file is the cleanest illustration so far. It will not be the last.

This publication treated the Unusual Whales aggregation as a wire pointing to the underlying reporting rather than as primary sourcing in itself; the structural claim rests on the public statements, which are dated and attributable.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/unusual_whales
• https://t.me/unusual_whales
• https://t.me/unusual_whales
• https://t.me/unusual_whales
• https://t.me/polymarket